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Background:Collectrin is required for membrane expression of the broad neutral amino acid transporters (B0AT1 and -3).
Results: Collectrin activates B0AT1 and B0AT3 in a discrete interaction region of the transporters.
Conclusion: A potential conserved ancillary protein binding region in B0AT1/B0AT3 mediates collectrin interactions.
Significance: This is the first example of a potential common interaction site for multiple solute carrier 6 family ancillary
proteins.
Many solute carrier 6 (SLC6) family transporters require
ancillary subunits to modify their expression and activity. The
main apical membrane neutral amino acid transporters in
mouse intestine and kidney, B0AT1 and B0AT3, require the
ancillary protein collectrin or ACE2 for plasma membrane
expression. Expression and activity of SLC6 neurotransmitter
transporters are modulated by interaction with syntaxin 1A.
Utilizing monocarboxylate-B0AT1/3 fusion constructs, we dis-
covered that collectrin is also necessary for B0AT1 and B0AT3
catalytic function. Syntaxin 1A and syntaxin 3 inhibit the mem-
brane expression of B0AT1 by competing with collectrin for
access. A mutagenesis screening approach identified residues
on trans-membrane domains 1, 5, and 7 on one face of B0AT3
as a key region involved in interaction with collectrin. Mutant
analysis established residues thatwere involved in collectrin-de-
pendent functions as follows: plasma membrane expression of
B0AT3, catalytic activation, or both. These results identify a
potential binding site for collectrin and other SLC6 ancillary
proteins.
The SLC6 family includes secondary active amino acid and
neurotransmitter transporters, which are involved in a broad
variety of physiological functions,most notably neurotransmit-
ter uptake at the synapse and epithelial amino acid transport in
kidney and intestine (1). B0AT1 (SLC6A19) catalyzes the sec-
ondary active transport of neutral amino acids across the apical
membrane in the small intestine and kidney, whereas B0AT3
(SLC6A18) is found only in the kidney (2). Both transporters
require collectrin or angiotensin-converting enzyme 2 (ACE2)
as an essential subunit for trafficking to the plasma membrane
in all in vitro and in vivo expression systems tested to date (3–9).
B0AT1, however, retains a small amount of residual activity and
membrane expression when expressed alone in Xenopus laevis
oocytes (7, 10, 11). Indirect evidence suggests that human
B0AT3 is nonfunctional (12); glycine/alanine transport at the
human renal brush border is instead mediated by the proton-
dependent transporter PAT2 (SLC36A2) (9). The molecular
interactions, stoichiometry, and basis of stabilization of B0AT1
and B0AT3 by collectrin/ACE2 have not yet been described in
detail. With the exception of SIT1 (SLC6A20) (13), no other
transporter in the SLC6 family appears to require het-
erodimerization to reach the cell surface. Most neurotransmit-
ter transporters in this family rather require homodimerization
and/or oligomerization to exit the endoplasmic reticulum
(14–16).
Mutations in B0AT1 are the cause of the autosomal reces-
sive Mendelian inherited condition Hartnup disorder (17,
18). Characterized by renal aminoaciduria and intestinal
malabsorption, the disorder is normally benign but has been
associated with a diverse array of symptoms, including skin
rash, cerebellar ataxia, and psychosis (2). B0AT1 knock-out mice
replicate human Hartnup disorder and also display a complex
metabolic phenotype resulting in enhanced insulin sensitivity (19,
20). Consistent with an essential role of collectrin and ACE2 in
traffickingandtissuedistributionofB0AT1andB0AT3, collectrin-
deficient mice lack B0AT1 and B0AT3 in the kidney, whereas
ACE2-deficient mice lack B0AT1 in the intestine (3, 5). Collectrin
has also been associatedwith glucose-stimulated insulin secretion
from pancreatic -cells in vitro and in vivo (21–23) and
aldosterone-independent high sodium-induced hypertension
(23–26). Both genes are under the transcriptional control of the
transcription factors HNF1 and HNF4 (27). B0AT1 has also
been shown to interact with aminopeptidase N in the intestine
(28). ACE2 is involved in a number of pathologies due to its role in
the degradation of angiotensin II (29–31). With regard to its role
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inaminoacid transporter trafficking, lackofACE2hasbeenshown
to aggravate intestinal inflammation (32).
Despite these important roles in vital metabolic processes,
information on the interaction between collectrin/ACE2 and
B0AT1 or B0AT3 is scarce. It is thought to involve a conserved
Arg-240 residue in B0AT1 (Arg-225 in B0AT3) (7). Intriguingly,
this mutation did not affect B0AT1 when expressed alone but
reduced transport severely in the presence of collectrin/ACE2
(2). Several other Hartnup disorder mutations, namely Ala-69
and Pro-265, have also been implicated in ACE2 and collectrin-
mediated B0AT1 dysfunction (5).
Although the dependence of B0AT1 and B0AT3 surface
expression on collectrin appears unique, protein-protein inter-
actions between SLC6 neurotransmitter sodium symporters
and smaller membrane-anchored proteins is widespread (14,
33–37). For instance, syntaxin 1A, a 288-residue type 1 single-
pass T-SNARE protein, which regulates vesicular fusion events
in the nervous system via formation of coiled-coil bundles with
other SNARE proteins (38, 39), has been shown to interact with
NET, DAT, SERT, GAT1, and GLYT2 (33–35, 40–43). In par-
ticular, the relationship between the neurotransmitter sodium
symporters -aminobutyric acid (GABA) transporter GAT1
and syntaxin-1A has been well characterized (33). Syntaxin
1A modulates GAT1-mediated GABA uptake, efflux,
exchange, and subcellular redistribution (44–49). The net
result of these molecular interactions is an 75% reduction in
the turnover rate of GAT1, although surface expression is
increased at the same time (33). Syntaxin 1A paralogs are also
involved in membrane protein regulation in epithelial cells (50,
51), and syntaxin isoforms in kidney and small intestinal epi-
thelium localize in a manner that suggests a potential role in
apical and basolateral cell polarity (52, 53). Although it is often
inferred from evidence of interactions with SNARE proteins
that collectrin may mediate vesicular fusion events and forma-
tion of SNARE complexes, no direct evidence for this has been
shown (23, 54, 55). Even for syntaxin 1A,molecular interactions
with other membrane proteins have been shown to be both
SNARE complex-dependent and -independent (49, 56).
In this study we undertook a systematic study of molecular
interactions between B0AT1/3 and collectrin. We report here
that collectrin is essential for catalytic activation, and we iden-
tify the molecular interaction site of collectrin with B0AT3. In
addition, we identify cross-reactivity between collectrin and
syntaxin proteins, which regulate B0AT1 expression.
Experimental Procedures
Molecular Cloning and DNA Manipulation—Molecular
cloning of transporters andmurine collectrin has been reported
previously (6, 7, 17). Monocarboxylate transporter fusion con-
structs rMCT1-B0AT1 and rMCT1-B0AT3 were generated
using overlap extension PCR on cDNA templates. The rMCT1
sense primer was designed to incorporate an XbaI cutting site
and Kozak motif, before the start codon. The B0AT1 antisense
primer comprised anXbaI site, and theB0AT3 antisense primer
comprised an EcoRI site. The overlap primers contained 21 bp
from each cDNA in either sense or antisense orientation
excluding stop and start codons. Molecular cloning of murine
syntaxin 1A was conducted using mRNA isolated from mouse
brain as a template (RNeasy Plus, Qiagen). Other syntaxins
were cloned using kidney mRNA. Superscript IITM reverse
transcriptase (Life Technologies, Inc.) was used to synthesize
the cDNA, followed by PCR amplification with gene-specific
primers and Pfu polymerase (Agilent). Sequences for all primer
pairs are available upon request. For syntaxin 1A and 7, HindIII
restriction endonuclease sites were incorporated in both the 5-
and 3-cloning primers. For syntaxin 3, EcoRI restriction endo-
nuclease sites were added to the 5 and 3 ends of the cloning
primers. Mouse ACE2 (mACE2) truncation primers were
designed based onmultiple pairwise alignments of mACE2 and
mouse collectrin and used to delete residues 18–580 and
18–500 from mACE2. 18–580 retains the collectrin homo-
logy consensus sequence, beginning just downstream of the
consensus start site (mACE2–591). 18–500 was designed to
retain an in silico identified tyrosine-based ER sorting signal
(ELMaccession ELME000120) annotated atmACE2(510–513)
which may be important for trafficking to the plasma mem-
brane. The N-terminal signal peptide (residues 2–18) was
retained in both constructs. Following amplification, DNA
fragment size was verified using agarose gels. DNA was then
purified (Wizard SV, Promega) and digested before ligation
(Quick ligase, New England Biolabs) into the pGHJ X. laevis
oocyte expression vector.
For CHO cell experiments, syntaxin 1A and syntaxin 3 were
subcloned frompGHJ vectors into the pcDNA3.1mammalian
expression vector using the same HindIII (syntaxin 1A) and
EcoRI (syntaxin 3) endonuclease sites as were used for the orig-
inal cloning. Subcloning was verified by restriction digests. All
other cloning products were verified by sequencing (Biomo-
lecular Resource Facility, Australian National University). All
pcDNA3.1 syntaxin constructs were isolated using an endo-
toxin-free midi DNA preparation (NucleoBond Xtra EF Plus,
Macherey-Nagel) before transfection into mammalian cell
cultures.
Preparation of X. laevis Oocytes and Expression of Proteins—
X. laevis oocytes were surgically removed and prepared for
cRNA injection as described previously (57). Maintenance of
animals and preparation of oocytes was approved by the Aus-
tralian National University animal ethics review board (ANU
Protocol A2014/20). Synthetic RNA (cRNA) was prepared for
injection and in vitro protein expression in oocytes also as
described previously (28) with the followingmodifications. The
pGHJ-basedvectorscontaining transporterandchaperonecon-
structs were linearized using SalI HF (New England Biolabs) for
2 h orNotI (New England Biolabs) overnight. Following in vitro
synthesis and purification, cRNA was quantified using a nano-
drop spectrophotometer (A260/A280) and diluted to the appro-
priate concentration.
Uptake Experiments—Radiolabeled uptake experiments in
oocytes were conducted as described previously (10, 28). For
cRNA titration experiments, cRNAs were injected in different
ratios as indicated in the experiments. Mouse syntaxin cRNA
titrations were fitted to the single competitive binding site
Equation 1,
y  A2  A1 
A2
1  10 x  log x0
(Eq. 1)
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where A1 and A2 are the maximum and minimum horizontal
(ordinate) asymptotes, respectively.
Electrophysiological Recordings—Electrophysiological record-
ings were conducted as described previously (10, 57) with some
modifications. Briefly, all steady-state recordings were made
with an Axon Geneclamp 500B amplifier (Axon Instruments).
Voltage clamp was routinely set to 50 mV, and data were
sampled at 3 Hz using pClamp 8.2 software (Axon Instru-
ments). Oocytes were chosen for recording when they had a
resting membrane potential 25 mV 	 Vm 	 35 mV. Sub-
strate dependence was measured by a stepwise exchange of
substrate concentrations using a run-up and run-down series of
concentrations for each oocyte. The general oocyte assay buffer
1
ND96, pH 7.4 (96mMNaCl, 2mMKCl, 1mMMgCl2, 1.8mM
CaCl2, 5 mM HEPES, titrated with NaOH), was used as the
control solution for all electrophysiological recordings unless
otherwise indicated.
For simultaneous measurements of L-[U-14C]lactate uptake
and L-alanine-induced currents, oocytes were superfused with
ND96, pH 7.4, buffer and clamped to50mV. The gravity flow
of ND96, pH 7.4, was then stopped, and the bath outflow pump
was allowed to evacuate the bath to a volume of 100 l. A
100-l volume of 10 mM L-alanine and 0.5 mM L-[U-14C]lactate
was then added to the bath solution to give a final concentration
of 5 mM L-alanine and 0.25 mM L-[U-14C]lactate. Subse-
quently, recordings upon application of both substrates were
continued for 10min to allow for a sufficient quantifiable flux of
charge and radiolabeled L-lactate into oocytes. Recordingswere
stopped and oocytes washed three times with 200 l ice-cold
ND96, pH 7.4, before being transferred individually to scintil-
lation vials and prepared for radioactivity quantification.
Surface Biotinylation, Whole Membrane Preparation and
Western Blotting—Surface biotinylation of oocytes has been
described previously (28). Whole membrane preparation was
used to determine protein expression and degradation in
oocytes. Fifteen oocytes per experimental condition were trit-
urated in 1 ml of oocyte homogenization buffer (100 mMNaCl,
50mMTris-HCl, pH7.6, 1mMEDTA, pH8.0, Complete EDTA-
free protease inhibitor (Roche Applied Science)) until homog-
enized. The homogenate was cleared by centrifugation (2000

g, 4 °C, 10 min). Subsequently, total membranes were isolated
by centrifugation at 140,000
 g at 4 °C for 30 min (OptimaTM
Max, Beckman). The resulting supernatant was aspirated, and
the pellet was washed twice with homogenization buffer before
being solubilized in 50 l of homogenization buffer containing
4% (w/v) SDS.
For preparation of CHO cell membranes, cells were washed
three times with phosphate buffered saline (PBS) (137 mM
NaCl, 2.7 mMKCl, 5mMNa2HPO4, pH 7.4) supplemented with
CaCl2 (0.9 mM) andMgCl2 (0.5 mM) before scraping off cells in
the same buffer. Cells were then centrifuged for 5 min at 500

g, resuspended in hypo-osmotic buffer (10 mM HEPES, pH 8.0,
15 mM KCl, 2 mM MgCl2, 0.1 mM EDTA), and incubated for 5
min on ice. Lysed cells were then homogenized with a hypoder-
mic needle and centrifuged at 600
 g for 10min to pellet dense
cell debris before the supernatant was transferred and centri-
fuged at 150,000
 g at 4 °C for 60min. The resulting pellet was
dissolved in 5 mM glycine, and a Bradford assay conducted to
determine total protein concentration.
Membrane proteins were subjected to SDS-PAGE analysis as
described previously (28). Nitrocellulose membranes were
incubated with the following primary antibody dilutions: rabbit
anti-mouse B0AT1 (1:3000) (custom antibody, Pineda Anti-
body Service); sheep anti-mouse collectrin (1:2000) (R &D Sys-
tems); rabbit anti-mouse B0AT3 (1:200) (custom antibody,
Pineda Antibody Service); rabbit anti-human syntaxin-1A
(1:1000) (Cell Signaling Technology); rabbit anti-mouse ACE2
(1:4000) (Abcam); and rabbit anti-mouse -actin (1:2000)
(Abcam). For detection, horseradish peroxidase (HRP)-con-
jugated donkey anti-rabbit or anti-sheep IgG was used at the
same dilution as the primary antibody, except for anti-rabbit
IgG against mouse B0AT3 (1:1000).
Generation of CHO-cells Stably Expressing SLC6A19 and
Collectrin—CHO-SLC6A19-collectrin clone 1 was obtained by
a two-step process. CHO-Flip In (Life Technologies, Inc.) cells
were transfected with the plasmid pCDNA5/FRT-human
SLC6A19 using LTX-Lipofectamine (Life Technologies, Inc.).
Cells growing in the presence of hygromycin and expressing
SLC6A19, as demonstrated by RT-quantitative PCR, were sub-
sequently transfected with the plasmid pCDNA3.1-collectrin.
Double-transfected cells selected by their ability to grow in the
presence of hygromycin and G418 were subcloned by limited
dilution and analyzed with respect to the expression of both
SLC6A19 and collectrin as well as for sodium-dependent
uptake of leucine.
CHOCell Uptake and Transient Transfection of Syntaxin 1A
and 3 in CHO-SLC6A19-collectrin—Parental CHO cells were
cultured andmaintained in Ham’s F-12 GlutaMAXmedia (Life
Technologies, Inc.) supplementedwith 10% FBS and 100g/ml
Zeocin (Life Technologies, Inc.). CHO-SLC6A19-collectrin sta-
bly transfected cells were cultured and maintained in Ham’s
F-12 GlutaMAX supplemented with FBS (10% v/v and the anti-
biotics hygromycin (0.33 g/ml) (Life Technologies, Inc.)) and
G418 (0.275 g/ml) (Life Technologies, Inc.). Cells were pas-
saged over 7-day intervals with media replaced every 72 h.
Experiments were conducted on cells with passage numbers
from 3 to 10. For radiolabeled uptake assays, cells were seeded
out in 35-mm culture dishes (Nunc) and grown for48 h until
80% confluent. Before uptake, cells were washed three times
with Hanks’ buffered salt solution (HBSS,2 pH 7.4). Subse-
quently, uptake of radiolabeled compounds was measured at
37 °C for 6 min in HBSS (pH 7.4). When Na-independent
uptake was measured, NaCl in HBSS was replaced by NMDG-
Cl. To terminate transport, cells were washed three times with
ice-coldHBSS, pH7.4.After aspiration, cellswere lysedwith 0.1
M HCl, scraped together, and homogenized by trituration.
Aliquots were used for scintillation counting and protein
quantification.
For transient expression of pcDNA3.1 constructs, cells
were seeded into 35-mm dishes and transfected using Lipo-
fectamine LTX reagent (Life Technologies, Inc.) as recom-
2 The abbreviations used are: HBSS, Hanks’ buffered salt solution; TM, trans-
membrane; NMDG,N-methyl-D-glucamine; PDB, Protein Data Bank; POPC,
1-palmitoyl-2-oleoylphosphatidylcholine; MD, molecular dynamics.
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mended by the manufacturer. After incubation for48 h, cells
were used for radiolabeled uptake assays.
RNAi Knockdown of Syntaxin 1A and Syntaxin 3—Small
interfering RNAs for CHO syntaxin 1A and 3 were selected
from mouse MISSION predesigned siRNA (Sigma) binding to
sequence regions that are 100% identical to the corresponding
Chinese hamster sequences. CHO-SLC6A19-collectrin cells
were transfected with the RNAi pairs when 30–50% confluent
using 50 pmol of RNAi per target (Lipofectamine RNAiMAX,
LifeTechnologies, Inc.) and incubated at 37 °C for a further 48 h
before experimental use. To verify silencing, total RNA was
extracted from transfected cells (Macherey-Nagel, Nucleo-
Spin RNA), and 1 g was reverse-transcribed into cDNA
(Superscript II, Life Technologies, Inc.). For semi-quantitative
analysis, transcripts were amplified for 25 cycles. FollowingRT-
PCR, samples were loaded onto a 1% (w/v) agarose gel and
quantified using UV densitometry after running and staining
(SYBR Safe, Life Technologies, Inc.).
Homology Models of B0AT3 and Creation of Collectrin TM
Domain—The PROMALS3D server was used to generate a
structure-based alignment of mouse B0AT3 (mB0AT3) using
protein sequence of LeuT fromAquifex aeolicus strainV5 (Uni-
Prot O67854) or Drosophila melanogaster dopamine trans-
porter DAT (UniProt Q7K4Y6) (58). The following settings
were used: identity threshold  1, secondary structure
weight 0.1, and amino acid weight 0.5. Minor adjustments
were then made to the structure-based sequence alignments to
reflect a lack of consensus or hydropathy overlap between them
based on a previously established multiple sequence alignment
of LeuT to SLC6 neurotransmitter transporters (59). Based on
this alignment mouse B0AT3 (mB0AT3) homology models
were generated using the Swiss model server with both LeuT
from A. aeolicus (PDB 2A65) or theD. melanogaster dopamine
transporter DAT (PDB code 4m48) as the nearest homologue
with a known x-ray crystal structure as the template for model
building. Validation of homology models was conducted as
reported previously (28). Collectrin is 222 amino acids in length
and has been predicted to contain a single-helicalmembrane-
spanning domain (Val-142 to Ile-166) (TMHMM version 2.0).
To ensure that sufficient residues were included to extend
beyond the span of the membrane, residues Met-136 to Arg-
171 were modeled as an ideal -helix using SwissPdbViewer
(60).
Docking of Collectrin and Molecular Dynamics Simu-
lations—To investigate the possible interaction interface
between mB0AT3 and collectrin, the mB0AT3 and collectrin
models were docked using the HADDOCK webserver (61).
Based on the experimental predictions for the proposed pro-
tein-protein interface between mB0AT3 and collectrin, resi-
dues in and around helix 7 of mB0AT3 were defined as the
active docking interface, although residues fromcollectrinwere
treated as passive. Six docking simulations were performed, in
which different subsets ofmB0AT3 residueswere defined as the
active residues, as outlined in Table 1. The docking results were
manually analyzed to determine the conformation that best fit a
combination of the following criteria: 1) the lowest docking
score; 2) the greatest number of interacting residues between
mB0AT3 and collectrin; and 3) the conformation in which both
mB0AT3 and collectrin adopted a transmembrane orientation.
The best fitmB0AT3/collectrin conformationwas embedded in
a pre-equilibrated 1-palmitoyl-2-oleoylphosphatidylcholine
(POPC) bilayer (62) and used as the starting conformation to
initiate molecular dynamics (MD) simulations. To avoid the
introduction of inappropriate charges, the N and C termini of
both mB0AT3 and collectrin were capped by acetylation and
amidation, respectively.
All MD simulations were performed using the GROMACS
(Groningen Machine for Chemical Simulation) package, ver-
sion 3.3.3, using the GROMOS 54A7 force field (63). The sim-
ple point charge water model (64) was used to describe the
solvent water. All simulations were performed under periodic
boundary conditions in a rectangular box. The dimensions of
the box were chosen such that the minimum distance of the
protein to the box wall was at least 1.0 nm. A twin-range
method was used to evaluate the nonbonded interactions.
Interactions within the short-range cutoff of 0.9 nm were
updated every step. Interactions within the long-range cutoff of
1.4 nm were updated every three steps together with the pair
list. A reaction field correction was applied using a relative
dielectric constant of 	r  78.5 to minimize the effect of trun-
cating the electrostatic interactions beyond the 1.4-nm long-
range cutoff (65). The SHAKE algorithm (66) was used to con-
strain the lengths of the covalent bonds. The geometry of the
water molecules was constrained using the SETTLE algorithm
(67). To extend the time scale that could be simulated, explicit
hydrogen atoms in the protein were replaced with dummy
atoms, the positions of which were calculated each step based
on the positions of the heavy atoms to which they were
attached. This eliminates high frequency degrees of freedom
associated with the bond angle vibrations involving hydrogens,
allowing a time step of 4 fs to be used to integrate the equations
of motion without affecting thermodynamic properties of the
system significantly (68). The simulations were carried out in
the NPT-ensemble at T 300 K, and P 1 bar. The tempera-
ture (T) and pressure (P) weremaintained close to the reference
values by weakly coupling the system to an external tempera-
ture and pressure bath using a relaxation time constant of 0.1 ps
(69) and 0.5 ps, respectively. The pressure coupling was semi-
isotropic. Data were collected every 40 ps for analysis. Images
were produced using VMD (70).
To initiate the simulation, 1000 steps of steepest descent
energy minimization were performed. Then the system was
equilibrated over a 10-ns period inwhich the position restraints
were gradually lowered from 1000 to 500 to 100 to 50 to 10
kJ/mol/nm2 in successive 2-ns simulations. This gradual lower-
ing of position restraints reduces the backbone fluctuations
TABLE 1
The list of docking sets and the correspondingmB0AT3active residues
For details see under “Experimental Procedures.”
Docking set mB0AT3-active residues
1 225, 283, 287, 296, 502
2 210, 268, 283, 286, 272
3 6, 10, 194, 210, 268, 286, 492
4 205, 210, 268, 286, 492
5 6, 10, 194, 210, 218, 280, 286, 492
6 280, 283, 286
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often associated with homology models in MD simulations
(71). After equilibration, all position restraints were removed;
new velocities were assigned, and a further 10-ns unrestrained
MD simulation was performed to allow the protein-protein
interface to adopt an equilibrated conformation. Note, because
of the well documented structural limitations of homology
models in MD, simulations were not extended beyond 10 ns
(71).
Statistical and Data Analysis—A Shapiro-Wilk normality
test was used to ensure that experimental data sets in oocyte
experiments were drawn from a normally (i.e. Gaussian) dis-
tributed population. All experimental data are given asmean
S.D. The number of biological repeats (experiments) is given as
e, and the number of technical repeats is given as n. Multivari-
ant experiments were analyzed for significance using one-way
analysis of variance tests. The Bonferroni post hoc test was used
to compare between pairs ofmeans for significance. Probability
values (p values) of significance thresholds for one-way analysis
of variance are indicated in the figure legends. To verify corre-
lation between variables for Eadie-Hofstee and other linear
regressions, Pearson’s correlation coefficient (r) was deter-
mined; adjusted R2 values were hence derived to test for good-
ness of fit of linear functions. Kinetic parameters K0.5 and Vmax
valueswere first derived by fitting individual current recordings
to either the Michaelis-Menten Equation 2
I 
ImaxS
K0.5 S
(Eq. 2)
or the Hill Equation 3.
I 
ImaxS
n
K0.5
n Sn
(Eq. 3)
Individual curves were averaged and refitted. Nonlinear curve
fitting using linear regressions of kinetic data were conducted
using the Eadie-Hofstee Equation 4.
I   K0.5
I
S
 Imax (Eq. 4)
All data manipulation and statistical analyses were performed
using OriginPro 9.1 (OriginLab) with the exception ofWestern
blot and agarose gel UV densitometry, which was performed
using ImageJ version 1.48 (http://imagej.nih.gov/ij/).
Results
Functional Interactions between SLC6 Amino Acid Trans-
porters and Ancillary Proteins Collectrin and ACE2—As
reported previously, collectrin and ACE2 are essential to func-
tionally express mouse B0AT1 and B0AT3 (Fig. 1A) (3, 4, 7–9).
It is important to note that human B0AT3 is an inactive protein
even if coexpressed with ACE2 or collectrin (Fig. 1A). Mouse
and human B0AT1 display a small transport activity in the
absence of the ancillaries, whereas mouse B0AT3 does not. It
appears that the same domains of ACE2 and collectrin interact
with B0AT1 and B0AT3 as exemplified by the virtually
unchanged transport induction of mouse B0AT1 by a collectrin
homologous truncation of ACE2(18–580) compared with
full-length ACE2 (Fig. 1B).
We and others have previously shown that neither collectrin
nor ACE2 change the substrate affinity of B0AT1 (3, 7, 28).
Mouse B0AT3, by contrast, demonstrated differential substrate
affinity for its main substrates L-glycine and L-alanine when
coexpressed with either collectrin or ACE2 (Fig. 1C). The
apparent affinity (K0.5) for L-alanine was 0.79 0.14 mM in the
presence of collectrin, whereas in the presence of ACE2 a value
of 0.14  0.02 mM was measured. For glycine, the K0.5 was
0.99 0.05 and 0.27 0.06mM in the presence of collectrin and
ACE2, respectively. To see whether the substrate specificity
was also ancillary partner-dependent, we measured uptake of
L-[14C]alanine in the presence of 10 mM of a range of amino
acids (Fig. 1D). Consistent with the increased apparent affinity
of glycine and alanine in the presence of ACE2, a higher degree
of inhibition was observed in the presence of unlabeled glycine
and alanine. Serine and threonine showed a similar behavior. By
contrast, no incremental change of the maximum substrate-
induced transport current (Imax) induced by alanine and glycine
and other substrates was observed, when currents were nor-
malized to the methionine-induced current in the presence of
either ancillary protein (Fig. 1E). These results demonstrate
that collectrin and ACE2 are not only trafficking subunits, but
they also affect substrate affinity and specificity of the B0AT3
transporter. As a result, these subunits may also be involved in
the catalysis of substrate movement by B0-like transporters.
Collectrin Is Necessary for the Catalytic Function of B0AT3
and B0AT1—To differentiate between the trafficking function
of collectrin and any potential role in the catalytic process, we
created a tandem transporter with the rat monocarboxylate
transporter 1 (MCT1) (Fig. 2A). Rat MCT1 is readily expressed
at the oocyte surface due to the expression of theXenopus Basi-
gin protein that is involved in trafficking of MCT1 to the cell
surface (72). We first created a MCT1-B0AT3 construct, as
B0AT3 has no activity when expressed alone (see Fig. 1A). Sur-
prisingly, we found that MCT1-B0AT3 did not transport L-ala-
nine in the absence of collectrin (Fig. 2B). In contrast, when
collectrin was coexpressed with MCT1-B0AT3, full L-alanine
transport activity was restored. MCT1-B0AT3 showed active
FIGURE 1.Ancillary proteinsmodify substrate affinity of B0AT1 and B0AT3. X. laevis oocytes were injected with 10 ng of the indicated transporter, 2 ng of
collectrin, and 10 ng of ACE2 cRNA in the indicated combinations exceptwhere otherwise stipulated. All uptake and electrophysiologicalmeasurementswere
madeday 4–6post-injection.A,uptake of 100M L-[U-14C]leucine or 100M L-[U-14C]alaninewasmeasured in oocytes expressing B0AT1or B0AT3over 30min.
Each bar representsmean S.D. (n 12, e 3. B, B0AT1was coexpressedwith truncated (18–500del or 18–580del) or wild-type ACE2. Uptakewasmeasured
as in A (n 1012, e 3). a and b above the individual bars indicate groupings of conditions whose differences of means are not statistically significant from
each other at the p 0.05 level.C, oocyteswere voltage-clamped at50mV and then perfusedwith serial concentrations of L-alanine. Datawere transformed
according toEadie-Hofstee andanalysedby linear regression, for all regressions 0.99R20.88, andPearson’s r0.94 (n7).D,oocyteswere injectedwith
6 ng of B0AT3 cRNA, 5 ng of ACE2, and 2 ng of collectrin cRNA. Uptake was measured as in A with the exception that it was challenged by 10 mM unlabeled
L-amino acids as indicated. The first pair of bars from the left represents unchallenged 100M L-[U-14C]alanine uptake. L-[U-14C]Alanine uptake fromuninjected
oocytes was subtracted. Each bar represents mean S.D. (n 810, *, p	 0.05). E, oocytes were perfused with 10mM of all the amino acids indicated on the
abscissa, and subsequent steady-stateNa currentswere recorded. All currentswere normalized to themaximal current inducedby 10mM L-methionine. Each
bar represents mean S.D. (n 6, e 3).
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L-lactate transport comparable with MCT1 alone, either with
or without collectrin coexpression (Fig. 2C). AnMCT1-B0AT1
construct displayed similar dependence on collectrin coexpres-
sion as theMCT1-B0AT3 construct (Fig. 2D). To further inves-
tigate whether collectrin-induced activity of B0AT1 and B0AT3
was proportional to the surface expression of the tandem con-
struct, we used the natural variability of transporter expression
in oocytes. Rat MCT1 is electro-neutral (73) allowing us to
compare B0AT3 currents with L-[14C]lactate uptake. These
experiments demonstrated a strong correlation between lactate
uptake and alanine-induced currents (Fig. 2E). However, the
magnitude of L-alanine-induced charge fluxes (Q5 mM L-ALA)
was generally lower in MCT1-B0AT3/collectrin coexpressing
oocytes than those coexpressing native B0AT3/collectrin.
To investigate thebehaviorof theMCT1-B0AT3tandemcon-
struct further, we measured basic kinetic parameters. Inspec-
tion of the original tracings suggested that alanine-induced cur-
rents saturatedmore readily in the tandem construct compared
with the conventional transporter (Fig. 3A). Consistent with
Fig. 2E, the Vmax of alanine-induced currents was significantly
lower in the tandem construct plus collectrin (26.8  2.3 nA)
compared with B0AT3 plus collectrin (97.6  13.5 nA) (Fig.
3B). The K0.5 value of alanine-induced currents was also signif-
icantly lower in the tandem construct plus collectrin (0.15 
0.03 mM) compared with B0AT3 plus collectrin (0.79  0.18
mM). This combination of a change in both steady-state kinetic
parameters explains why we observed similar rates of transport
in both native B0AT3 and the fusion construct at sub-K0.5 L-al-
anine concentrations in uptake assays (Fig. 2B). No L-alanine-
induced currents were observed in MCT-B0AT3-expressing
oocytes in the absence of collectrin (data not shown), confirm-
ing the necessity of collectrin for sodium-driven transport
activity in MCT-B0AT3. Together these results clearly demon-
strate an essential role of collectrin in both trafficking and cat-
alytic activation of B0AT3.
Identification of a Collectrin Interaction Site in B0AT3—To
identify the potential binding site(s) for collectrin in B0AT3 and
B0AT1, we used mutagenesis-based approaches and sequence
alignments of the SLC6 family. A summary of the results for all
mutants is given in Table 2. Mutations were selected by a num-
ber of processes as follows: (i) mutations associated with imi-
noglycinuria in humans (6); (ii) protein sequence differences
between mouse B0AT3 (active in oocytes) and human B0AT3
(inactive in oocytes); (iii) potential sites for electrostatic inter-
actions between collectrin and B0AT3; and (iv) molecular
dynamics simulation of collectrin binding to B0AT3 in the
vicinity of Arg-225 (equivalent to B0AT1 Arg-240). We delib-
erately excluded mutations of residues lining the translocation
pore as these are likely to be involved in substrate and ion bind-
ing. The relative activity of single mutations was mapped onto
the homology model of B0AT3 (Fig. 4, A and B).
Several mutations causing functional changes of B0AT3
activity, D21N, Q25V, L213W, R225T, N283D, D287N, and
S296R, were found on one face of the B0AT3 homology model
in transmembrane (TM) domains 1, 5, 7 and adjacent cytoso-
lic and extracellular regions. Mutants Y72H, K90T, S158D,
M297S, I456T, L477P, and Q568R, by contrast, had no signifi-
cant effects onB0AT3 transport activity and,with the exception
of M297S, were facing the side of the transporter opposite
TM1, -5, and -7. A space-filled rendering of B0AT3 shows TM
domains 5 and 7 are separated by a groove in the side of the
transporter, with the mutated residues D21N, Q25V, L213W,
R225T, N283D, D297N, and S296R surrounding this groove
(Fig. 4C). TM1 is proposed tomove during the transport cycle
through this gap between TM5 and TM7 (74). All mutated
B0AT3 variants with the exception of D502Nwere expressed in
oocytes at comparable protein levels towild-type B0AT3 (Table
2).With the exception ofmutantsH50Y,G78S, L213W,R225T,
and N283D, transport activity was highly correlated with sur-
face expression (Table 2). This is illustrated by the correlation
coefficient (r), which increased from 0.87 to 0.99 when the five
mutants were excluded. Mutants H50Y and G78S were not
investigated further as they are not located at the cell surface.
As there seems to be a preponderance of functional and surface
expression mutants in B0AT3 TMs 5 and 7, we hypothesized
that the collectrin’s TM domainmay occupy an interaction site
in the groove flanked by these TM domains.
To test this notion, a series of six docking simulations
between collectrin TM domain and B0AT3 were performed,
using different sets of residues from TM5 and TM7 as docking
constraints (Table 1). The lowest scoring docking conformer
was used to initiate a 10-nsmolecular dynamics simulation (see
under “Experimental Procedures”). This simulation identified
Met-297 in TM7, Leu-213 in TM5, and Gln-25 in TM1 as key
interacting residues with collectrin’s TM domain (Fig. 4D). Fig.
4, C and D, appears different in the loop regions as they are
based on DrosophilaDAT and LeuT crystal structures, respec-
tively. The TM5/TM7 groove is present in both homology
models and the experimental structures on which they were
based.
Next, we sought to differentiate whether these residues in
TM1, -5 and -7 interact directly with collectrin or affect the
transporter independently of it. To do so, we hypothesized the
existence of three different types of mutations that could cause
FIGURE 2. Collectrin is required for catalytic activation ofmouse B0AT3 and B0AT1. X. laevis oocytes were injectedwith 10 ng of the indicated transporter
or 18 ng of MCT-B0AT3 fusion cRNA and 2 ng of collectrin cRNA. All measurements were made days 4–6 post-injection of cRNA. A, schematic of B0AT3
expression conditions are as follows: B0AT3 alone cannot traffic to the plasma membrane (panel i) because it requires collectrin (panel ii). We hypothesized it
would trafficwithout collectrinwhen fused toMCT1 (panel iii). B,uptake of 100M L-[U-14C]alanine or 100M L-[U-14C]lactatewas carried out over 30min. Each
histogram bar representsmean S.D. (n 1015, e 3). a–c above the individual bars indicate groupings of conditions whose differences of means are not
statistically significant from each other at the p 0.05 level. C, uptake of 100 M L-[U-14C]lactate was carried out over 24 min. Each histogram bar represents
mean S.D. (n10, e3).a andb above the individualbars indicates groupingsof conditionswhosedifferences ofmeans arenot statistically significant from
each other at the p 0.05 level. D, uptake of 100M L-[U-14C]leucine or 100M L-[U-14C]lactate was carried out over 25min. Each bar represents mean S.D.
(n 1215, e 3). a–d above the individual bars indicate groupings of conditionswhose differences ofmeans are not statistically significant fromeach other
at the p 0.05 level. E, correlation between L-lactate uptake and L-alanine-induced currents in the MCT-B0AT3 tandem construct. The integral of the alanine-
dependent inward charge transfer (Q5 mM L-Ala) was calculated and plotted against the L-[U-14C]lactate uptake in the same oocyte (n 10 13). Pearson’s r
0.92, the adjusted coefficient of determination (R2) is indicated on the graph.
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loss of function in B0AT3. The first are catalytic mutations that
interfere directly with the transport mechanism, independent
of collectrin. A second type of mutation interferes with the
interaction between collectrin and B0AT3 resulting in a traf-
ficking modification. These should be rescued when expressed
in the MCT1-B0AT3 tandem construct. A third type of muta-
tion affects the catalytic role of collectrin and should not be
rescued when incorporated into the tandem construct.
Although it is difficult to discriminate between nonfunctional
type 1 and type 3 mutants, a true type 3 mutant is likely to be
A
B
FIGURE 3. Properties of MCT-B0AT3 activation by collectrin. X. laevis oocytes were injected with 10 ng of the indicated transporter or 18 ng of MCT-B0AT3
fusion cRNA and 2 ng of collectrin cRNA. All measurements were made 4–6 days post-injection. All oocytes were voltage-clamped at50 mV. A, L-alanine-
induced current tracings recorded from single oocytes super-fused with the serial substrate concentrations were used to determine the steady-state kinetics
of MCT-B0AT3 compared with B0AT3, both in the presence of collectrin. Steady-state inward currents were recorded for both the descending (shown) and
ascending (not shown) order of L-alanine concentrations. B, oocytes were perfused with serial concentrations of L-alanine as in A and averaged data for each
concentration fitted to the Michaelis-Menten function. Inset, Eadie-Hofstee linear regression of the Michaelis-Menten data: adjusted R2  0.77 for B0AT3 
collectrin and adjusted R2 0.88 for MCT-B0AT3 collectrin (n 810, e 3).
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expressed at the cell surface. A possible type 3mutant is L213W
(located in TM5) as it is neither active in B0AT3 nor in the
auto-traffickedMCT1-B0AT3 when both are coexpressed with
collectrin (Fig. 5A). Furthermore, it is localized and fully
expressed at the plasma membrane (Fig. 5B). N283D can be
classified as a type 2 mutant; it lacks surface expression and
activity when coexpressed with collectrin, but it is re-activated
in MCT-B0AT3 by the presence of collectrin (Fig. 5, B and C).
The TM1 mutant B0AT3(D21N) is also type 2 but with an
opposite effect. It consistently shows higher surface expression
when coexpressed with collectrin, but it shows wild-type-like
activity when expressed in the tandem construct in the pres-
ence of collectrin. Thus, both D21N and N283D change traf-
ficking but display wild-type-like activity in the tandem con-
struct. Both of these mutants are likely to interact with
collectrin.
A mix between type 2 and 3 is represented by R225T; the
mutant has an almost complete loss of surface expression, but it
regains limited activity in the auto-trafficking MCT-B0AT3 con-
struct in the presence of collectrin (Fig. 5, B and D). Another
type 2/3mutant is B0AT3(Q25V),which is partially active in the
presence of collectrin despite having a strong trafficking defect,
as shown byWestern blotting after surface biotinylation (Fig. 5,
B and E). However, transport activity of MCT-B0AT3(Q25V)
was even lower in the presence of collectrin, suggesting that
Gln-25 is also important in the catalytic activation by collectrin.
In most transporters of the SLC6 family, Gln-25 is an acidic
residue (Asp or Glu). Replication of the negative charge
(B0AT3(Q25D)) caused a total loss-of-function in both B0AT3
and the tandem construct when coexpressed with collectrin
(Fig. 5E). Membrane expression was consistent across all
mutants in the tandem construct as ascertained by L-[U-
14C]lactate uptake (Fig. 5F).
Interactions with Syntaxin-1A and Syntaxin 3—Protein-pro-
tein interactions with single-pass trans-membrane helical
chaperones or ancillary proteins is a common feature in the
SLC6 family (33). Syntaxin 1A, in particular, has been shown to
interact with a number of neurotransmitter transporters (33).
We therefore wondered whether the collectrin binding region
identified here represents a common interaction site. The
GABA transporter GAT1 (SLC6A1) has been shown to interact
with syntaxin 1A at aspartate residues in the N terminus of the
transporter (44, 46, 48), which is part of our identified collectrin
binding region in B0AT3 and B0AT1. For syntaxin and collec-
trin interaction experiments, we utilized mouse B0AT1, as it
has a larger transport signal than mouse B0AT3, and small but
resolvable levels of collectrin-independent transport activity
and cell surface expression. In confirmation of published
results, we found that the presence of murine syntaxin 1A sig-
nificantly reduced rat GAT1-mediated GABA transport (Fig.
6A) (46). Coexpression of collectrin and syntaxin 1A with rat
GAT1 recovered GABA transport to a similar rate observed
with GAT1 expressed alone. When expressed with GAT1
alone, collectrin slightly, but significantly, increased transport
activity. Similarly, B0AT1 transport activity, measured in the
absence of collectrin, was virtually abolished when it was coex-
pressedwith syntaxin 1A.Coexpressionwith collectrin resulted
in reconstitution of80% of transport observed in the absence
of syntaxin 1A. A similar inhibition of L-alanine transport activ-
ity was observed when syntaxin 1A was coexpressed with
B0AT3 and collectrin (data not shown). To determine themode
of action of syntaxin 1A, we titrated syntaxin 1A cRNA against
B0AT1 and collectrin cRNA (Fig. 6B). Surface expression of
B0AT1in the presence of collectrinwas very sensitive to expres-
sion of small amounts of syntaxin 1A. This effect could be
reversed by increasing collectrin cRNA (Fig. 6C). However, this
reversal required large amounts of collectrin cRNA (10–20
ng/oocyte). Notably, increasing titration of collectrin reduced
the apparentmolecularmass of B0AT1 from about 80 to 65 kDa
(Fig. 6C). L-Leucine uptake rates of B0AT1 confirmed the sup-
pression of B0AT1-mediated activity by syntaxin 1A in the
presence of collectrin (Fig. 6D). Functional recovery was
TABLE 2
Summary of single residue mutations in murine B0AT3, co-expressed with collectrin: selection, position, activity, and expression
mB0AT3
mutation
Selection
categorya
Mutation
position
L-U-14CAlanine uptake activity
(% wild-typeS.E., e> 3)
Plasma membrane expression
(normalized to WT expression)
Relative protein expression
(normalized to WT expression)
Orthologous residue
in human B0AT1
Wild type 100 1 1
D21N 3 N terminus 167.5 9.6b 1.86 0.25 0.96 Asp-36
Q25V 4 TM1 32.0 11.0b 0.29 0.09 0.86 Gln-40
Q25D 4 TM1 3.9 5.0b 0.05 0.07 0.84 Gln-40
H50Y 2 EL 1 141 11.3b 0.80 0.15 1.21 His-65
Y72H 2 TM2 79.0 10.3 0.89 0.11 1.20 Tyr-87
G78S 1 IL 1 15.3 1.8b 0.89 0.19 0.88 Gly-93
K90T 2 IL 1 72.5 13.4 0.86 0.24 0.90 Ser-106
S158D 3 EL 2 115.2 5.6 1.25 0.12 1.46 Asp-173
L213W 4 TM5 30.3 8.5b 1.10 0.18 1.14 Thr-228
R225T 3 TM5 10.2 2.7b 0.39 0.15 1.07 Arg-240
N283D 2 IL 3 4.9 1.5b 0.21 0.03 1.32 Asn-298
D287K 3 TM7 3.5 2.4b 0.10 0.12 1.03 Asp-302
D287N 3 TM7 21.0 12.6b 0.21 0.06 1.08 Asp-302
S296R 2 TM7 2.6 0.6b 0.09 0.07 1.01 Gly-311
M297S 4 TM7 104.0 5.6 0.96 0.10 0.77 Phe-312
M297C 4 TM7 117.2 4.8 1.39 0.42 0.84 Phe-312
I456T 2 TM9 110.7 6.7 1.05 0.23 1.12 Phe-471
G464N 2 EL 5 90.0 10.8 0.94 0.55 1.08 Gln-479
L477P 1 TM10 120.0 26 1.21 0.38 0.81 Ile-492
G495R 1 IL 5 3.9 3.3b 0.01 0.02 0.76 Gly-510
D502N 3 IL 5 9.3 6.8b 0.12 0.11 0.07 Asp-517
Q568R 2 EL 6 91.4 9 0.92 0.49 0.93 Tyr-583
aMutagenesis selection categories are as follows: 1, iminoglycinuria-associated mutants; 2 evolved between murine and human B0AT3; 3 electrostatically mediated in-
teractions in cytosolic and extracellular loops; and 4 in silicomolecular dynamic-associated (for details of mutant selection see under “Experimental Procedures”).
b p	 0.05 one-way analysis of variance;, Bonferroni post hoc test was conducted for all repeats that make up the tabulated data.
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observed when the amount of collectrin cRNA was increased,
confirming competition between both ancillary proteins. The
inhibition of B0AT1-mediated transport activity fitted well to a
single competitive binding site equation (Fig. 6D, inset).
Although our data suggest competition for a common binding
site between collectrin and syntaxin-1A, the cellular expression of
both proteins does not overlap (38). Database searches comparing
tissue-specific E.S.T. expression data (www.ncbi.nlm.nih.gov) and
literature searches (52, 53), however, identified several syntaxin
isoforms (3, 4, 7 and 17) with overlapping expression to B0AT1
and/or collectrin. Coexpression experiments showed strong inhi-
bition of B0AT1 collectrin activity by syntaxin 3, whereas syn-
taxin 7 had no effect (Fig. 6E).
To confirm syntaxin 1A and 3 inhibition of B0AT1-mediated
leucine uptake in a different expression system, we generated
stably transfected CHO cells expressing human B0AT1 and
human collectrin.CHO-SLC6A19-collectrin cells showed a sig-
nificant increase in the sodium-dependent uptake of leucine
above CHO parental cells (Fig. 7A). Expression of both B0AT1
and collectrin was confirmed by Western blotting and immu-
nodetection in whole membrane preparation (Fig. 7B). CHO
parental cells exhibited no B0AT1 or collectrin expression (Fig.
7B). As observed in oocytes, transient expression of either syn-
taxin 1A or syntaxin 3 in CHO-SLC6A19-collectrin cells signif-
icantly reduced sodium-dependent uptake of leucine compared
with pcDNA3.1 vector-only controls (Fig. 7C, left panel). We
also discovered that both syntaxin 1A and 3 are endogenously
expressed in CHO-SLC6A19-collectrin cells (Fig. 7D). If com-
petition with collectrin and syntaxin occurs, we reasoned that
silencing of endogenous syntaxin would increase B0AT1-medi-
FIGURE 4. Surface localization of B0AT3 mutants displayed on a homology model. Transport activity of all mutants is indicated by color coding and was
determined by flux assays in X. laevis oocytes as described in Fig. 1. Data were taken from Table 2. The homology model structure of mouse B0AT3 was built
using theD.melanogaster dopamine transporter DAT x-ray crystal structure in the outward open confirmation (PDB 4m48) (A–C) or LeuT from A. aeolicus in an
outward occluded confirmation (PDB 2A65) (D) as a template. Mouse B0AT3 is viewed parallel to themembrane. Mutated residues are shown in van derWaals
representation.Wild-type activity is 100% (white); lower activity is displayed in red, andhigher activity inblue.A, transmembranehelices 1, 5, and7 are colored
yellow, orange, and green, respectively. B, homology model is rotated 180° on its vertical axis. C, surface representation of B0AT3 in the same orientation as
shown in A. The pocket is flanked by TM domains 5 and 7 and partially occupied by TM1. Only mutants located in, or peripheral to, TM1, TM5, or TM7 are
labeled.D, hypothesized interaction site between collectrin’s TM domain (Met-136–Arg-171) and B0-like transporters. Themodel is based on the end point of
a 10-ns MD simulation (see “Experimental Procedures”). The same face of mouse B0AT3 is shown as in other panels. The transporter is viewed parallel to the
membranewith thePOPCmembraneusedduringMDsimulation removed to see theproteins clearly.MouseB0AT3 is visualized ingraywith collectrinMet-136
to Arg-171 in dark green. The same residues are shown as in C.
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ated leucine uptake. Accordingly, RNAi against both syntaxin
1A and syntaxin 3 led to an increase in sodium-dependent leu-
cine uptake (Fig. 7C, right panel). Simultaneous RNAi of both
mRNAs had a small cumulative effect on the inhibition of
sodium-dependent uptake. RT-PCR analysis confirmed signif-
icant reduction of syntaxin 1A and syntaxin 3 mRNA after
siRNA transfection (Fig. 7D).
Discussion
In this paper we report for the first time that collectrin is not
only required for trafficking of B0AT1 and B0AT3 to the plasma
membrane, but also for catalytic activation. We also note here
for the first time that human B0AT3 is an inactive protein,
which is consistent with evolution from B0AT3-mediated gly-
cine/alanine uptake in mice to PAT2-mediated glycine/alanine
uptake in humans (9) and the absence of glycinuria in humans
with homozygous nonsensemutations in B0AT3 (6).Moreover,
we report the localization of a collectrin interaction region in
B0AT3, positioned in a groove between TM5 and -7 of the
transporter, which also contains TM1 in all experimentally
isolated structural conformations of the SLC6 ancestors LeuT
and Drosophila DAT (74–77). Interestingly, the groove sug-
gested here to harbor collectrin is occupied by a cholesterol
molecule in the DAT outward open structure (75). The authors
suggest that cholesterol may stabilize the transporter in the
outward open conformation, which is consistent with func-
tional studies of the human serotonin transporter (78). We
would thus propose that collectrin and syntaxin isoforms can
occupy this binding site, increasing or inhibiting transport
activity, respectively. In the occluded structure of LeuT, TM1
and the cytoplasmic end of TM5 are in contact but become
separated during the transition to the cytoplasmic-facing
conformation (74–76, 79, 80). If collectrin would reduce the
activation energy of the transporter’s rate-limiting step, it
could speed up the transport cycle. Syntaxin isoforms by
contrast could stabilize transporter conformations other
than the rate-limiting transition state, thereby slowing down
transport. Syntaxin 3 could have a physiological role in reg-
ulating the transporter by displacing collectrin and thus
inhibiting B0AT1.
Our results clearly demonstrate a dual role of collectrin. It is
required for trafficking of the transporter to the cell surface and
is required for the catalytic activity. Both functions can be sep-
arated. L213W is involved in the catalytic activation of the
transporter, although it is located10 Å from the ionic radius
of the second sodium-binding site in the DAT-based outward
openhomologymodel; and it is even further away fromall other
predicted ion/substrate-binding sites. In contrast, type 2
mutants N283D and D21N selectively affect trafficking to the
cell surface. The remaining nonfunctional mouse B0AT3
mutants, the previously identified R225T (R240Q in B0AT1) (7)
andQ25V, were classified as type 2/3 and appear to be involved
in both collectrin-mediated functions. Alternatively, the small
but significant reduction of the B0AT1molecular weight, when
coexpressed with collectrin (see, for example, Fig. 6C) maybe
associated with its activation. Themechanism of this activation
remains to be elucidated, but it may involve recruitment of
additional proteins.We cannot rule out the possibility that nei-
ther collectrin nor syntaxin proteins directly bind to B0-like
transporters. They may interact indirectly through other pro-
teins, although there is evidence for direct interaction and colo-
calization between B0AT1, collectrin, and ACE2 from mouse
kidney and intestinal epithelial tissue (3, 28).
In contrast to collectrin, syntaxin 1A mediates an opposing
bi-functional effect (33). It enhances trafficking of GAT1 to the
surface, but at the same time reduces its activity. Several lines of
evidence are converging to establish the N-terminal domain
andTM1 of SLC6 transporters as a key domain in establishing
conformational equilibrium and intracellular gating (81–83).
This region also represents a binding/interaction region for
syntaxin 1A to the SLC6 serotonin transporter SERT (44, 48,
84), the norepinephrine transporter NET (42), and a Caenorh-
abditis elegans dopamine transporter DAT-1 (41). Although
the N-terminal domain has been implicated in syntaxin bind-
ing, our results, for the first time, suggest binding of syntaxin to
a groove between helix 5 and 7. This interaction would most
likely be mediated by the membrane anchored domain of syn-
taxin, a region shown to be crucial to the syntaxin 1A-mediated
regulation of GAT1 (44). The intracellular loop 4 (IL 4) region
of GAT1 has also been shown to inhibit GABA transport via an
arginine-rich domain that competes with syntaxin 1A for bind-
ing to the transporter’s N-terminal domain (44). Only Arg-420
in human GAT1 (Lys-455 in human B0AT1) is conserved by
chemical identity across solute carrier transporters in the IL 4
region, and we did not investigate the role of the IL 4 region in
the B0-like transport-collectrin interaction.
The interactions between collectrin and the B0-like trans-
porters cannot involve canonical coiled-coil domains as these
are absent in collectrin. It may, however, involve different stoi-
chiometric combinations with collectrin and/or associations
between SNARE proteins as has been described in pancreatic
-islet cells (23, 54, 55). To date, the only structural analysis of
collectrin comes from islet cells and islet cell cultures, where
disulfide-mediated dimerization, N-linked glycosylation, and
partial proteolysis by an extracellular protease regulate collec-
trin-associated insulin secretion and cell mass (22, 85). One
unexplained aspect of the effect of catalytic activation by
collectrin on B0AT3 is the significant increase in substrate
affinity when the transporter is auto-trafficked to the plasma
FIGURE 5.Analysis ofmutants in aMCT-B0AT3 tandemconstruct supports a bi-functional role for collectrin.A–E, X. laevis oocyteswere injectedwith the
indicated constructs and uptake of 100 M L-[U-14C]alanine measured over 30 min. Each bar represents the mean S.D. activity of n 1015 (e 3). a–d
above the individual bars indicate groupings of conditions whose differences of means are not statistically significant from each other at the p 0.05 level. B,
surface biotinylation and detection of collectrin and B0AT3was carried out as indicated under “Experimental Procedures.”Molecularmassmarkers (in kDa) are
indicated on the left, and detected proteins are indicated on the right. No TP no transporter. F, uptake of 100 M L-[U-14C]lactate by wild-type andmutated
MCT-B0AT3 tandem constructs. Lactate uptake for all conditions was normalized to lactate uptake of wild-typeMCT-B0AT3-expressing oocytes from the same
batch (i.e. eitherwith orwithout collectrin). Eachbar representsmean S.D. Nodifference at thep	 0.05was detected for lactate uptakebetweenMCT-B0AT3
WT and any MCT-B0AT3 mutant (n 1015, e 3).
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A B
C D
E
FIGURE 6. Interactions between B0AT1, collectrin, and syntaxin 1A. Uptake measurements in X. laevis were performed as outlined in Fig. 2. A, cRNA was
injected as follows: transporter 10ng/oocyte; collectrin 2ng/oocyte; syntaxin-1A 5ng/oocyte. Uptake of 100M L-[U-14C]alaninewasmeasured over 30
min. Each bar represents the mean S.D. (n 1015, e 3). a–c (GAT1) and d–f (B0AT1) above the individual bars indicate groupings of conditions whose
differences of means are not statistically significant from each other at the p  0.05 level. B, collectrin cRNA  2 ng/oocyte B0AT1 cRNA  10 ng/oocyte.
Syntaxin-1A cRNA was titrated as indicated. Surface biotinylation was carried out with 15 oocytes as described under “Experimental Procedures.” Molecular
mass markers (in kDa) are added to the left, and the detected proteins are indicated on the right. C, syntaxin-1A cRNA  5 ng/oocyte B0AT1 cRNA  10
ng/oocyte. Collectrin cRNAwas titrated as indicated. 15 oocytes per sample were treated as in B. D, uptake of 100M L-[U-14C]leucine was carried out over 30
min. For each condition, one ancillary protein cRNA was injected at a constant amount, and the other ancillary cRNA was titrated as indicated in the legend.
Each data point represents mean S.D. (n 1015, e 3). E, cRNA was injected as follows: B0AT1 10 ng/oocyte; collectrin 2 ng/oocyte; all syntaxins
5 ng/oocyte. Uptake of 100 M L-[U-14C]leucine was carried out over 30 min. Each bar represents mean S.D. (n 15, e 3). a–d above the individual bars
indicate groupings of conditions whose differences of means are not statistically significant from each other at the p 0.05 level.
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membrane as part of the MCT-B0AT3 fusion construct. This
construct could have an effect on the overall conformation of
the transporter resulting in a slight change of the on- or
off-rates of transporter substrates, which in turn would alter
the affinity.
We believe that in light of its dual role and identified binding
region collectrin should now be viewed as an essential subunit
of a heteromultimeric secondary active transporter, rather than
simply as an ancillary protein or chaperone.
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